GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » Cyclically Adjusted PB Ratio

Interpace Biosciences (Interpace Biosciences) Cyclically Adjusted PB Ratio : 0.04 (As of Apr. 27, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Interpace Biosciences Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Interpace Biosciences's current share price is $1.50. Interpace Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $34.08. Interpace Biosciences's Cyclically Adjusted PB Ratio for today is 0.04.

The historical rank and industry rank for Interpace Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

IDXG' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.04   Max: 0.71
Current: 0.04

During the past years, Interpace Biosciences's highest Cyclically Adjusted PB Ratio was 0.71. The lowest was 0.01. And the median was 0.04.

IDXG's Cyclically Adjusted PB Ratio is ranked better than
94.66% of 131 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.98 vs IDXG: 0.04

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Interpace Biosciences's adjusted book value per share data for the three months ended in Dec. 2023 was $-14.173. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $34.08 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Interpace Biosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Interpace Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Cyclically Adjusted PB Ratio Chart

Interpace Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.07 0.02 0.03

Interpace Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.03

Competitive Comparison of Interpace Biosciences's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Interpace Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Cyclically Adjusted PB Ratio falls into.



Interpace Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Interpace Biosciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.50/34.08
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Interpace Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Interpace Biosciences's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-14.173/129.4194*129.4194
=-14.173

Current CPI (Dec. 2023) = 129.4194.

Interpace Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201403 204.556 99.695 265.546
201406 191.069 100.560 245.905
201409 165.521 100.428 213.304
201412 130.994 99.070 171.124
201503 102.586 99.621 133.271
201506 61.606 100.684 79.189
201509 35.054 100.392 45.190
201512 73.815 99.792 95.730
201603 45.730 100.470 58.906
201606 32.996 101.688 41.994
201609 -8.143 101.861 -10.346
201612 30.011 101.863 38.130
201703 36.541 102.862 45.975
201706 18.091 103.349 22.655
201709 15.878 104.136 19.733
201712 14.323 104.011 17.822
201803 14.268 105.290 17.538
201806 13.674 106.317 16.645
201809 12.734 106.507 15.473
201812 5.383 105.998 6.572
201903 9.390 107.251 11.331
201906 8.071 108.070 9.665
201909 6.178 108.329 7.381
201912 -1.142 108.420 -1.363
202003 -9.817 108.902 -11.667
202006 0.419 108.767 0.499
202009 -16.908 109.815 -19.926
202012 -7.171 109.897 -8.445
202103 -19.313 111.754 -22.366
202106 -8.681 114.631 -9.801
202109 -9.258 115.734 -10.353
202112 -10.111 117.630 -11.124
202203 -10.491 121.301 -11.193
202206 -11.336 125.017 -11.735
202209 -14.505 125.227 -14.991
202212 -14.679 125.222 -15.171
202303 -14.505 127.348 -14.741
202306 -14.428 128.729 -14.505
202309 -14.503 129.860 -14.454
202312 -14.173 129.419 -14.173

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Interpace Biosciences  (OTCPK:IDXG) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Interpace Biosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Interpace Biosciences (Interpace Biosciences) Business Description

Traded in Other Exchanges
Address
300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.
Executives
Christopher Mccarthy officer: Principal Financial Officer C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal director 2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell director, officer: President and CEO 1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin 10 percent owner 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel officer: Chief Financial Officer REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca director C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan director C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p. 10 percent owner 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy director 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership 10 percent owner 55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev director, 10 percent owner C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg officer: Chief Accounting Officer INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard officer: Chief Commerical Officer C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054

Interpace Biosciences (Interpace Biosciences) Headlines

From GuruFocus

Interpace Biosciences Announces Path Forward in Letter to Shareholders

By GlobeNewswire GlobeNewswire 02-17-2021